Ignacio
Bernabeu Morón
Universidade de Santiago de Compostela
Santiago de Compostela, EspañaPublicacións en colaboración con investigadores/as de Universidade de Santiago de Compostela (35)
2024
-
Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study
European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 421-433
2023
-
Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly
Clinical Endocrinology, Vol. 99, Núm. 4, pp. 378-385
2022
-
Data mining analyses for precision medicine in acromegaly: a proof of concept
Scientific Reports, Vol. 12, Núm. 1
2021
-
Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas
Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819
-
Pasireotide in the Personalized Treatment of Acromegaly
Frontiers in Endocrinology, Vol. 12
2020
-
Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey
Pituitary, Vol. 23, Núm. 2, pp. 129-139
-
Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
Endocrine, Vol. 70, Núm. 3, pp. 575-583
-
GFRα 1-2-3-4 co-receptors for RET Are co-expressed in Pituitary Stem Cells but Individually Retained in Some Adenopituitary Cells
Frontiers in Endocrinology, Vol. 11
-
Molecular profiling for acromegaly treatment: a validation study
Endocrine-related cancer, Vol. 27, Núm. 6, pp. 375-389
2019
-
Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly
EBioMedicine, Vol. 43, pp. 537-552
2018
-
Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus
Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 5, pp. 297-305
-
Expert document on management of acromegaly
Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 8, pp. 428-437
2017
-
Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement
Pituitary, Vol. 20, Núm. 5, pp. 489-498
-
Long-term outcome of multimodal therapy for giant prolactinomas
Endocrine, Vol. 55, Núm. 1, pp. 231-238
-
Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer
Oncogene, Vol. 36, Núm. 5, pp. 652-666
2016
-
Long-term treatment with pegvisomant for acromegaly: A 10-year experience
Clinical Endocrinology, Vol. 84, Núm. 4, pp. 540-550
2015
-
Hypopituitarism After Traumatic Brain Injury
Endocrinology and Metabolism Clinics of North America, Vol. 44, Núm. 1, pp. 151-159
-
Update on prognostic factors in acromegaly: Is a risk score possible?
Pituitary, Vol. 18, Núm. 3, pp. 431-440
2014
-
Cabergoline treatment in acromegaly: Pros
Endocrine, Vol. 46, Núm. 2, pp. 215-219
-
Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF
Endocrinology, Vol. 155, Núm. 11, pp. 4329-4340